Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of induction TPF followed by chemoradiotherapy with cisplatin versus cetuximab in unresectable locally advanced head and neck squamous cell carcinoma
2007-005540-24Phase 3Completed
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Feb 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, cisplatin, docetaxel and fluorouracil in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Primary endpoint: Overall survival. Started Feb 2008; status: completed.
02
Drugs
cetuximabcisplatindocetaxelfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-005540-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005540-24.